Jeff HelferJeffrey Helfer has a background that includes a total of 35 years in product development and manufacturing, new business development, and regulatory affairs, primarily in field of life sciences.
He currently serves as CEO of Diffinity Genomics, a company formed to commercialize novel nucleic acid (e.g. DNA) extraction, purification and analysis products. Previously, he served as CEO of MYOTECH, LLC a company formed to commercialize a unique human circulatory support system with the potential to save hundreds of thousands of lives worldwide, and VP of Engineering and New Business Development for Biophan Technologies, Inc. where he successfully developed new medical device technologies that led to business partnerships with Boston Scientific and Medtronic.
Prior to that, at Ortho-Clinical Diagnostics (O-CD), a division of Johnson & Johnson, he served as Program Director, responsible for the system integration of an $80 million new product development program. As O-CD’s Director of New Business Development, Helfer managed a $90 million annual R&D portfolio, led new business development initiatives, managed multiple new technology and product development partnerships, and licensed-in new products. While serving as a Director of Regulatory Affairs for O-CD, Helfer was responsible for helping to modify the company’s product regulatory approval processes. As O-CD’s Director of Engineering, he managed a 140 person engineering organization that delivered many new products to market.
Since leaving Corporate 50 companies in 2001, he has raised or helped to raise over 30 million dollars in start-up financing. He holds a B.S. (Summa Cum Laude) from Rochester Institute of Technology and an M.S. (Cum Laude) from the University of Rochester, both in Engineering, with additional graduate studies in business administration. Mr. Helfer also holds over 80 issued and applied patents.
|
